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1. Introduction 
Colorectal cancer screening for average risk individuals beginning at the age of fifty has 
been recommended by the American Cancer Society, the American College of 
Gastroenterology, the American Society for Gastrointestinal Endoscopy, the American 
Gastroenterological Association and the American College of Radiology (Levin et al., 2008). 
Colorectal cancer screening has been shown to reduce the incidence and mortality of cancer 
of the colon and rectum due to early detection and removal of precancerous lesions and 
adenomas. Colonoscopy is generally considered to be the preferred method of screening 
despite the emergence of computed tomographic (CT) colonography and the use of other 
recommended screening modalities (Rex et al., 2009). Other indications for colonoscopy 
(ASGE, 2000) include evaluation and treatment of gastrointestinal bleeding, unexplained 
iron deficiency anemia, clinically significant chronic diarrhea of unexplained origin, foreign 
body removal, decompression of acute nontoxic megacolon or sigmoid volvulus, balloon 
dilation of stenotic lesions and in palliative procedures for colonic obstructive or bleeding 
neoplasms. 
Colonoscopy requires thorough cleansing of the large intestine for full visualization as well 
as the safe and effective completion of the procedure. This chapter describes the rationale for 
bowel preparation, the types of preparations currently available, complications associated 
with bowel preparations and special considerations for bowel preparation in specific 
segments of the population. The consequences of inadequate bowel preparation, use of 
antibiotic prophylaxis for the procedure and management of anticoagulants and antiplatelet 
agents before and after colonoscopy will also be reviewed. Literature was accessed using 
MEDLINE (through March, 2011) for all relevant articles published in the English language. 
2. Preparing for colonoscopy 
2.1 Why prepare? 
Inadequate bowel preparation is responsible for up to one third of all incomplete 
colonoscopy procedures (Belsey et al., 2007). Poor preparation precludes up to 10% of 
examinations (Kazarian et al., 2008), negatively impacts the rate of overall polyp (Froehlich 
et al., 2005; Harewood et al., 2003) and adenomatous polyp detection (Thomas-Gibson et al., 
2006). In additional, poor bowel preparation raises costs due to aborted examinations 
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followed by repeated procedures.  In a study of 200 consecutive outpatient colonoscopies, 
imperfect bowel preparation resulted in a 12% increase in costs at a university hospital and 
22% increase in costs at a public hospital (Rex et al., 2002). 
2.2 Types of bowel preparations 
The ideal colon preparation should rapidly and reliably cleanse the colon of fecal material 
while having no effect on the gross or microscopic appearance of the colon (Wexner et al., 
2006). It should require a short period for ingestion and evacuation, cause no discomfort, 
and produce no significant fluid or electrolyte shifts while also being palatable, simple, and 
inexpensive. 
Agents used for bowel preparation can be divided into three main categories according to 
their mechanism of action, these being isosmotic, hyperosmotic, and adjunctive 
preparations. Polyethylene glycol-electrolyte lavage solutions (PEG-ELSs) and sodium 
phosphate (NaP) formulations are among the most commonly used. 
2.2.1 Isosmotic bowel preparations 
Isosmotic preparations that contain polyethylene glycol (PEG) are osmotically balanced, 
high-volume, nonfermentable electrolyte solutions (Table 1). These preparations cleanse the 
bowel with minimal water and electrolyte absorption or secretion in the bowel lumen and 
provide evacuation, primarily by the mechanical effects of a large-volume lavage. Standard 
dosing of the 4 liter PEG-ELS is 240 ml(8 oz.) every 10 minutes or a rate of 20 to 30 mL/min 
if administered by nasogastric tube. This intake rate is generally continued until the rectal 
output is clear or the entire volume of the preparation is ingested (Wexner et al., 2006). 
Because of the salty taste of PEG-ELS, sulfate-free PEG preparations were developed; 
patients by a 3:1 ratio preferred the sulfate free 4 liter PEG-ELS compared to the original 
formulation (76% versus 24%, p≤0.0001) with no difference in the efficacy of colonic 
cleansing (Di Palma and Marshall, 1990). To improve taste, flavored preparations have also 
been introduced. Unfortunately, flavorings may increase the osmotic load, and some contain 
carbohydrates that, with bacterial fermentation, could lead to production of combustible 
gases (Wexner, 1996). 
A further development for the advancement PEG-ELSs came with reduced volume 
preparations. Good or excellent cleansing was reported in 87% of the patients receiving 2-
liter PEG-ELSs combined with bisacodyl (irritant laxative tablets) (n=93) compared to 92% of 
patients receiving a 4-liter sulfate free PEG-ELSs (p=0.16). The lower volume preparation 
was associated with decreased abdominal fullness (p < 0.01), nausea (p < 0.01), vomiting (p 
= 0.01), and overall discomfort (p < 0.01) (Di Palma et al., 2003). For this regimen, dosing on 
the evening prior to the procedure consists of two 5 mg bisacodyl delayed release tablets 
followed after the first bowel movement by 240 mL of PEG-ELS preparation every 10 
minutes until the excreted effluent is clear or until a total of 2 L is ingested.  Only clear 
liquids are permitted on the day of the preparation. Another low volume PEG-ELS consists 
of the addition of ascorbic acid in the 2-L PEG solution, that is also dosed  240 mL every 10 
minutes split into two one 1 liter doses, each accompanied by 16 oz. of clear fluid for 
hydration.. This regimen permits a normal breakfast and lunch followed by a light dinner 
(clear soup or yogurt or both) on the day prior to the procedure, followed by bowel prep 
starting 1 hour after the evening meal. The second liter dose can be consumed 1.5 hours after 
the initial 1 liter or on the morning of the colonoscopy (Wexner et al., 2006).The 2 liter PEG 
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with ascorbic acid was compared to 4-liter PEG-ELS in a trial where successful gut cleansing 
was achieved in 136 of 153 (88.9%) cases of the 2 liter PEG with ascorbic acid group and 147 
of 155 (94.8%) cases of the 4 L PEG-ELS group. The 2 liter regimen was also associated with 
lower frequency of nausea (14% versus 23%; 95% confidence interval [CI], -17 to -1) and 
abdominal pain (3% versus 8%; 95% CI, -10 to -0.2).Patient ratings of acceptability and taste 
were better for the 2-liter PEG with ascorbic acid group than for the PEG-ELS group (P < 
0.025) with a higher completion rate of entire preparation (p=0.035) (Ell et al, 2008). 
Collectively, these studies suggest that the 2 liter preparations of PEG-ELS are as effective as 
and better tolerated than the 4 liter PEG-ELS preparations.  
Efficacy of the standard 4-L PEG-ELS preparation can be improved by administration of 
split doses, even with minimal dietary restriction before the first dose (El Sayed et al., 2003). 
Ingestion of the entire preparation on the day of the procedure about 5 hours before the 
colonoscopy has also been shown to improve the clean-out quality when compared with 
patients who received PEG-ELS the previous day (approximately19 hours before the 
procedure) (Church, 1998).  
2.2.2 Hyperosmotic bowel preparations 
Hyperosmotic bowel preparations have a mechanism of action of drawing water and 
electrolytes into the bowel lumen, stimulating fluid loss, peristalsis and evacuation. These 
small-volume preparations cause fluid shifts, accompanied by electrolyte alterations 
(Ehrenpreis et al., 1998; Lichtenstein, 2009). Of these, the most commonly used include oral 
NaP available in as tablets and an aqueous solution (now withdrawn from the US market). 
The aqueous NaP preparation contains monobasic and dibasic NaP. The solution form of 
NaP contains 90 ml of solution with each 45-mL dose containing contains 29.7 g NaP. Two 
doses of 45 mL aqueous solution are given at least 10 to 12 hours apart, with the second dose 
given within 5 hours of the procedure. Each of these solutions should be diluted in 8 oz of 
clear liquid with a minimum of l 16 oz of clear liquids to be consumed after each dose 
(Wexner et al., 2006). The first study(Vanner et al., 1990)  compared the 4 L PEG-ELS with 
the 90 ml NaP solution included 102 patients randomized to receive either oral NaP 
solution(n=54) or standard PEG-ELSs (n=48) prior to colonoscopy. Overall, good to excellent 
bowel cleansing was reported in a significantly higher number of patients who received 
sodium phosphate(80%) compared to the patients who received PEG-ELS(33%), (p<0.001). 
Completion of bowel preparation was also significantly higher in the NaP group (85%) 
compared to the PEG-ELS group (31%), (p<0.001). A recent meta-analysis reviewed 
randomized controlled clinical trials from 1990 to 2005 and compared the tolerability, 
efficacy, and safety of various preparations. Pooled data from 15 trials with 3293 patients 
that compared PEG and NaP preparations showed that 94.4% of patients completed taking 
NaP compared with 70.9% of patients taking PEG solution Using a random effects model, 
the odds ratio of completion of preparation was 0.16 (95% CI: 0.09–0.29; P < 0.00001) in favor 
of NaP (Tan and Tjandra, 2006). 
Two NaP tablet preparations are FDA approved for cleansing prior to colonoscopy. The 
original formulation (Visicol™) contained microcrystalline cellulose (MCC), an excipient 
and was thought to reduce mucosal visibility during colonoscopy, with a new MCC-free 
preparation now available (Osmoprep™). The dose is 40 tablets (60 g) for the MCC 
containing preparation and 32 tablets (48 g) for the MCC-free preparation, both divided into 
2 doses separated by 10 to 12 hours. 20 tablets are taken the night before the colonoscopy, 4 
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tablets every 15 minutes followed by 8 oz clear liquids and the remaining 12-20 tablets on 
the morning of the colonoscopy within 3-5 hours of the procedure. A split-dose NaP 
schedule, with one dose taken the day before and one on the day of the procedure separated 
by 12 hours, was also found to be superior relative to a single dose (Frommer, 1997). All 
NaP regimens should be taken with a minimum of 2 L of clear liquids. In the event that the 
bowel preparation is inadequate after the full dose of the NaP formulation, the reparation 
should be completed using a non-NaP formulation such as PEG-ELS (Wexner et al., 2006) 
Clinical studies have shown the original MCC containing NaP tablet formulation to be as 
efficacious and better tolerated than 4 liter PEG-ELS formulation and be equally as effective 
as an aqueous NaP solution. (Aronchick et al., 2000). The 32 tablet MCC free NaP tablet 
formulation has been shown to be at least as efficacious and better tolerated than the MCC 
containing formulation (Wruble et al., 2007) and also with better colon cleansing and 
tolerability compared to the 2 liter PEG-ELS formulation (Johanson JF et al.,2007). A 
prospective trial (Rex et al., 2006(B)) reported that patients receiving the 32 tablet NaP 
formulation (n=239) compared with the 40 tablet formulation (n=236) had significantly 
smaller increase in serum phosphate levels from baseline (3.5 mg/dl versus 4.4 mg/dl, 
p≤0.0002). This improvement must be tempered by the common occurrence of electrolyte 
and fluid imbalances as well as serious side effects from NaP containing preparations (see 
below). 
Recently a new sulfate based osmotic laxative(SUPREP) was approved by the FDA in 
August, 2010 for bowel preparation before colonoscopy containing sodium sulfate 17.5 g, 
potassium sulfate 3.13 g, magnesium sulfate 1.6 g in each 6 oz bottle. Sodium absorption in 
the small intestine with sodium sulfate preparations is largely reduced because of the 
absence of chloride, the accompanying anion necessary for active absorption against 
electrochemical gradient. Unlike oral sodium phosphate, sulfate salts do not produce renal 
tubular injury in animal models (Pelham, et al, 2009). 
A split dose (2-Day) regimen is advocated.  The efficacy of the oral sulfate solution (OSS) 
was compared with 4 liter sulfate free PEG-ELS in a multicenter, single-blind, randomized, 
non-inferiority study involving one hundred thirty-six outpatients undergoing colonoscopy. 
Successful or excellent bowel preparation was more frequent with OSS than with sulfate free 
PEG-ELS (98.4% versus 89.6%; P = .04 and 71.4% versus 34.3%; P < .001 respectively). 
Gastrointestinal side effects and adverse events were not significantly different between the 
2 groups (Rex et al., 2010). 
Other hyperosmolar bowel preparations include sodium picosulfate, a salt that has 
similar action as NaP, producing a cathartic effect by osmotic effect in the bowel. This 
preparation is commonly used alone and in combination with magnesium citrate outside 
of the United States, especially in the United Kingdom for bowel preparation for 
colonoscopy. A pooled analysis of 381 patients receiving sodium picosulfate and 369 
patients receiving sodium phosphate demonstrated a significantly higher efficacy in 
bowel cleansing (described as good or excellent cleansing), with the NaP formulation 
(90%) compared with sodium picosulfate (82%) (p =0.004). A similar adverse event profile 
was seen with the two preparations (Tan and Tjandra, 2006). The pooled analysis also 
demonstrated a similar efficacy of sodium picosulfate when compared to 4 liter PEG-ELSs 
with an additional reduction in the number of adverse events (48% versus 71% 
respectively, p=0.003). 
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Product (manufacturer) Active agent 
FDA 
approved 
(adults) 
Quantity 
Isosmotic    
Full volume    
Colyte (Scwarz Pharm, Mequon, Wis) PEG-3350 Yes  
Flavored   4000 ml 
Nonflavored   4000 ml 
GoLYTELY (Braintree, Braintree, Mass) PEG-3350 Yes  
Flavored   4000 ml 
Unflavored   4000 ml 
NuLYTELY (Braintree) 
PEG-
3350(sulfate 
free) 
Yes  
Flavored   4000 ml 
Nonflavored   4000 ml 
TriLyte (Scwarz Pharm) 
PEG-
3350(sulfate 
free) 
Yes  
Flavored   4000 ml 
Low volume    
Halflytely (Braintree) 
PEG-3350 and 
bisacodyl 
Yes 2000 ml 
MoviPrep (Salix , Morrisville, NC) 
PEG-3350 and 
ascorbic acid 
Yes 2000 ml 
Hyperosmotic    
Fleet Phospho-Soda EZ-Prep(oral) 
NaP 29.7 
grams/45 ml 
‡ 75 ml§ 
Visicol (tablet, NaP; Salix) 
NaP (oral) 
1.5 
grams/tablet 
Yes 
40 
tablets 
Osmoprep (MCC-free tablet, NaP; Salix) 
NaP (oral) 
1.5 
grams/tablet 
Yes 
32 
tablets 
Fleet enema (C.B. Fleet) 
Monobasic NaP 
Monohydrate-
19 g 
Dibasic NaP 
Heptahydrate- 
7 g 
Yes 118 ml 
SUPREP kit(Braintree, Braintree, Mass) 
In 6 oz-Na 
sulfate-17.5g, K 
sulfate-3.13 g, 
Mg sulfate 1.6 g 
Yes 360 ml 
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LoSoPrep kit (E-Z-EM Inc, Lake Success, NY) 
Mg citrate -18 g 
plus 20 mg 
bisacodyl oral 
and 10 mg 
suppository 
Yes 38.5 ml 
Magnesium citrate 
Mg citrate-17.45 
g 
Yes 300 ml 
Adjunctive medications    
Senna (AmerisourceBergen, Chesterbrook,PA)
Sennosides 
8.6 mg 
Yes Tablets 
Bisacodyl (Amkas) 
Bisacodyl 
5 mg 
Yes Tablets 
‡ FDA recommends against use of over-the-counter oral NaP for bowel preparation.  
§ C.B. Fleet ceased distribution and initiated a recall on December 11, 2008. 
Table 1. Agents used for bowel preparation 
Magnesium citrate is another hyperosmotic agent that also promotes release of 
cholecystokinin, resulting in fluid and electrolyte secretion as well as stimulation of 
peristalsis. It is typically not effective as a sole agent for colonic cleansing; hence it is used 
mainly in combination with other agents. Magnesium is renally excreted and should be used 
in extreme caution in patients with renal insufficiency or renal failure.. Sodium picosulfate 
in combination with magnesium citrate has been compared to 2 liter PEG-ELS with ascorbic 
acid with similar efficacy (73 % versus 84% respectively, p=0.367) and adverse event profile. 
Improved preparation was seen in the ascending colon (p=0.024) and cecum (p=0.003) 
(Worthington et al., 2008). Magnesium citrate in combination with 2 liter PEG-ELS solution 
has also been shown to improve preparation quality and improve patient satisfaction 
compared to 4 liter PEG-ELSs (Sharma et al., 1998). Combination preparations containing 
magnesium citrate also include a 240-mL dose of balanced magnesium solution and 20 mg 
bisacodyl(oral) the evening before the procedure and a 10-mg bisacodyl suppository the 
morning of the procedure (Delegge and Kaplan, 2005).A pulsed rectal irrigation with 
magnesium citrate as also been suggested to enhance preparation for colonoscopy; however, 
this requires skilled nursing for administration and is associated with a high cost (Chang et 
al, 1991). 
2.3 Additional medications/methods used in bowel cleansing 
2.3.1 Bisacodyl 
Bisacodyl is a poorly absorbed diphenylmethane which acts locally on the colon as a 
peristaltic stimulant. Its active metabolites stimulate colonic motility with an onset of action 
between 6 and 10 hours. It is often used as an adjunct with PEG-ELS although this 
combination has not demonstrated a significant difference in the quality of the preparation 
or amount of residual colonic fluid during colonoscopy (Ziegenhagen et al., 1992).Use of 
bisacodyl as an adjunct to PEG-ELS may allow patients to consume a smaller volume of 
PEG necessary for colonic cleansing (Sharma et al., 1998). 
2.3.2 Senna 
Senna is an anthraquinone derivative that is activated by colonic bacteria. These activated 
derivates have a direct effect on intestinal mucosa increasing the rate of colonic motility, 
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enhancing colonic transit and inhibiting water and electrolyte secretion. Like bisacodyl, 
senna can also be used as an adjunct to PEG-ELS. It has also been shown to reduce the 
amount of PEG-ELS required for effective bowel preparation (Iida et al., 1992). 
2.3.3 Flavoring 
Several methods to improve the palatability of both PEG-ELS and NaP solutions have been 
attempted. PEG-ELSs are now available in multiple flavors including cherry, citrus-berry, 
lemon-lime, orange and pineapple. Carbohydrate-electrolyte solutions such as Gatorade® 
and Crystal Light® have also been recommended to improve the taste in PEG and NaP 
solutions(Wexner et al.,2006).Other methods to improve taste that are often used in clinical 
practice include slowing the rate of consumption, chilling the solution and consuming 
lemon slices with preparations. 
2.4 Assessment of bowel preparation quality 
The American Society for Gastrointestinal Endoscopy (ASGE) and American College of 
Gastroenterology (ACG) Taskforce on Quality in Endoscopy have suggested that every 
colonoscopy report should include an assessment of the quality of bowel preparation. They 
proposed the use of terms such as “excellent,” “good,” “fair,” and “poor,” but admitted that 
these terms lack standardized definitions (Rex et al., 2006(A)). 
 One validated measurement of preparation quality is the Boston Bowel Preparation Scale 
(BBPS), which was developed to limit inter-observer variability in the rating of bowel 
preparation quality, while preserving the ability to distinguish various degrees of bowel 
cleanliness (Lai et al., 2009). The subjective terms previously described were replaced by a 3 
point scoring system applied to each of the 3 regions of the colon: the right colon (including 
the cecum and ascending colon), the transverse colon (including the hepatic and splenic 
flexures), and the left colon (including the descending colon, sigmoid colon, and rectum). 
The points are defined as follows: 0 = unprepared colon segment with mucosa not seen 
because of solid stool that cannot be cleared; 1 = portion of mucosa of the colon segment 
seen, but other areas of the colon segment not well seen because of staining, residual stool, 
and/or opaque liquid; 2 = minor amount of residual staining, small fragments of stool 
and/or opaque liquid, but mucosa of colon segment seen well; 3 = entire mucosa of colon 
segment seen well with no residual staining, small fragments of stool or opaque liquid. Each 
of the 3 segment scores is then summed for a total score of 0 to 9, in which 0 is unprepared 
and 9 is entirely clean. If an endoscopist aborts a procedure due to an inadequate 
preparation, then any nonvisualized proximal segments are assigned a score of 0.  An 
instructional video demonstrating the BPPS is available and can be accessed online at 
http://bmc.org/gastroenterology/research.htm (Lai et al., 2009). In a comprehensive 
validation study, the BBPS was found to be a reliable instrument for assessing bowel 
cleanliness during colonoscopy (Calderwood & Jacobson, 2010). 
2.5 Complications of bowel preparation 
2.5.1 Inadequate bowel preparation 
An inadequate preparation for colonoscopy can result in many complications including 
missed lesions, cancelled procedures, increased procedure time, and an increased potential 
in complication rates. Currently, there are no specific guidelines for the management of 
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patients in whom an adequate examination of the colon cannot be achieved due to an 
inadequate preparation. The ASGE has recommended the following “reasonable” approach: 
the same preparation can be repeated if the patient did not consume the preparation as 
prescribed, except not within 24 hours when using NaP because risk of toxicity. In patients 
who properly consumed the preparation, options include repeating the preparation with a 
longer interval of consuming clear liquids only before the preparation, switching to an 
alternative but equally effective preparation, adding another cathartic such as magnesium 
citrate, bisacodyl or senna to the previous regimen, or double administration of the 
preparation during a two-day period (with the exception of NaP). Combining preparations 
(example, PEG ELS and NaP solutions) may also be successful. 
2.5.2 Toxicities of bowel preparation 
With the exception of NaP containing preparations, most bowel preparations have been 
demonstrated to be safe to use in healthy individuals without significant comorbid 
conditions. Caution must always be taken in selecting a bowel preparation for patients with 
renal, hepatic or cardiac disease and those patients at the extremes of age. New data also 
suggests female gender and smaller body size are risk factors for complications of NaP 
preparations (Parakkal & Ehrenpreis, 2010). 
2.5.2.1 Oral sodium phosphate 
As of December 11, 2008 the FDA issued an alert about the safe use of oral NaP products 
and added a black box warning for acute phosphate nephropathy (Food and Drug 
Administration, 2008). The FDA alert also highlighted several patients at risk of developing 
this complication including individuals over the age of 55; patients who are hypovolemic or 
have decreased intravascular volume; people who have baseline kidney disease, bowel 
obstruction or active colitis; and those that are using medications that affect renal perfusion 
(such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor 
blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]). Females of 
smaller body size are an additional risk group (Ehrenpreis, 2009). 
Oral NaP preparations can cause fluid and electrolyte shifts secondary to the hyperosmotic 
nature of the products. It is often associated with the following abnormalities: 
hypernatremia, hypokalemia, hypocalcemia, decreased serum bicarbonate, and 
hyperphosphatemia (Ehrenpreis et al., 1997). Although electrolyte shifts are typically 
transient, clinically significant toxicities have been reported (Vanner et al., 1990). NaP 
preparations can also cause colonic mucosal abnormalities such as aphthoid erosions similar 
to those seen in inflammatory bowel disease and histologic findings including focal active 
inflammation, mucosal disruption and erosion, edema of the lamia propria, mucosal 
hyperemia, focal hemorrhage, lymphoid nodules and ulceration (Rejchrt et al., 2004). 
Physicians are advised to avoid using NaP preparations when evaluating patients with 
inflammatory bowel disease or patients with diarrhea of unknown etiology. 
2.5.2.2 PEG 
The most common adverse effects with PEG ELS are abdominal fullness, nausea and 
bloating. Rare events include Mallory-Weiss tears, esophageal perforation, toxic colitis, pill 
malabsorption, pulmonary aspiration, hypothermia, cardiac arrhythmias, PEG-induced 
pancreatitis and inappropriate antidiuretic hormone secretion (Clark & DiPalma, 2004). The 
www.intechopen.com
 
Preparing for Colonoscopy 
 
25 
use of PEG-based solutions is contraindicated in patients with gastric outlet obstructions, 
small and large intestinal obstruction, and suspected bowel perforation.  
2.5.2.3 Magnesium Preparations 
Magnesium citrate should be used with caution in patients with renal insufficiency or renal 
failure because it is eliminated by the kidney. Fatal reports and episodes of 
hypermagnesemia have been reported in patients with suspected or known renal failure or 
elderly patients (Schelling, 2000). 
3. Other considerations 
3.1 Antibiotic prophylaxis 
Transient bacteremia can occur during colonoscopy due to bacterial translocation of normal 
colonic flora into the bloodstream. Translocated bacteria may potentially adhere in remote 
tissues such as the endocardium. Antibiotic prophylaxis was commonly used in some high 
risk patients before colonoscopy, primarily to prevent infective endocarditis. However, the 
American Heart Association (AHA) and the American Society of Gastrointestinal 
Endoscopy (ASGE), in 2007 and 2008 respectively, have revised their recommendations 
regarding antibiotic prophylaxis before procedures including colonoscopy (Banerjee et al, 
2008; Wilson et al, 2007). Both societies classify cardiac patients as low, moderate, or high 
risk for endocarditis. New guidelines suggest that, antibiotic prophylaxis before including 
colonoscopy with or without biopsies or polypectomy is no longer recommended in any risk 
group including those considered to be high-risk.  This change in practice came about 
mainly because of a lack of convincing evidence to demonstrate a risk of endocarditis from 
gastrointestinal procedures. In addition, harmless bacteremia occurs in some daily activities 
such as tooth brushing. For example, in a study done by Lockhart et al., routine tooth 
brushing was associated with bacteremia in 23% of subjects (Lockhart et al, 2008). Bhanji et 
al. reported a 46% bacteremia rate (Bhanji et al, 2002), and Banerjee reported a 68% rate 
(Banerjee et al, 2008).  Bacteremia can occur after colonoscopy, with rates ranging from 0-
25%, and an average mean rate of 4.4% (Banerjee et al, 2008; Nelson, 2003). In contrast, a 
study done by Goldman showed that blood cultures were positive in 1% of patients after 
sigmoidoscopy (Goldman, 1985). Microorganisms causing transient bacteremia during and 
after gastrointestinal procedures are generally believed to have little potential to cause 
infective endocarditis. Normal skin floras are the most common organisms isolated from 
blood cultures after colonoscopy (although these could be a contamination during blood 
draw), (Llach et al, 1999; Levy, 2007). Despite more than 16 million colonoscopies and 
sigmoidoscopies that are done in each year in the United Stated (Seeff et al, 2004), there have 
been only 15 cases of infective endocarditis having a temporal relation with these 
procedures.  The potential side effects of prophylactic antibiotics to prevent an extremely 
small number of cases of infective endocarditis are felt to clearly outweigh their possible 
benefit (Banerjee et al, 2008; Wilson et al, 2007; Van der Meer, 1992).  
In cirrhotic patients with or without ascites in the absence of gastrointestinal bleeding who 
undergo colonoscopy, the risk of bacteremia is low. Llach et al. prospectively studied 58 
patients underwent colonoscopy. Four of these patients had positive blood cultures; none 
developed symptoms or signs of infections (Llach et al, 1999).  
Patients on peritoneal dialysis may be at risk for infectious complications of colonoscopy.  In 
fact, there are several case reports of peritonitis in patients on peritoneal dialysis after 
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colonoscopy especially following polypectomy (Bac et al, 1994; Ray et al, 1990). The 2005 
International Society for Peritoneal Dialysis (ISPD) recommendations state that these 
patients have antibiotic prophylaxis before any procedure involving abdomen and pelvis 
including colonoscopy, and emptying the peritoneal fluid prior to the  procedure (Piraino et 
al, 2005); however, these prevention strategies were not addressed in 2010 ISPD guidelines 
(Li et al, 2010). 
Antibiotic prophylaxis is not recommended by the ASGE before colonoscopy or any other 
GI procedures in patients who have prosthetic vascular grafts or cardiovascular devices 
such as pacemakers (Banerjee et al, 2008). However, the AHA recommends antibiotic 
prophylaxis for procedures occurring within the first 6 months of prosthetic vascular grafts 
while graft epithelialization is occurring (Wilson et al, 2007). 
Antibiotic prophylaxis is not recommended for patients who have prosthetic orthopedic 
devices undergoing colonoscopy, due to their low risk of infection (Banerjee et al, 2008). 
However, scattered cases of infections in prosthetic joints after colonoscopy have been 
reported (Vanderhooft et al, 1994; Cornelius et al, 2003). 
3.2 Management of antiplatelet agents 
Antiplatelet agents are used widely to treat patients with cardiovascular and 
cerebrovascular diseases as well as acute and chronic pain.  Aspirin and other nonsteroidal 
anti-inflammatory drugs (NSAID) are not believed to increase the risk of significant 
bleeding after colonoscopy whether biopsies and/or polypectomies are performed. Use of 
aspirin was not a risk factor for polypectomy-associated bleeding in a study of 1657 patients 
(Hui et al, 2004). Recommendations regarding the management of antithrombotic agents 
before endoscopic procedures published by the ASGE in 2009 classify the procedures from 
low-risk to higher-risk (see Table2). In addition, cardiovascular conditions are also classified 
from low-risk to higher-risk (see Table 3), (Anderson et al, 2009). Colonoscopy with or 
without biopsy is considered a low risk procedure, however if polypectomy is done, the risk 
is considered higher. The ASGE recommends that aspirin and NSAIDs should not be 
discontinued prior to colonoscopy if one of them is used alone and if their use is necessary 
in any of risk groups. There is some evidence that combination of aspirin and other NSAIDs 
increases the risk of bleeding after polypectomy (Grossman et al, 2010), thus discontinuation 
of NSAIDs two to three days before polypectomy is recommended in patients on combined 
therapy. 
Dipyridamole, another antiplatelet agent, used either  alone or in combination with aspirin 
may be continued in patients undergoing colonoscopy with no significant risk of bleeding, 
however its safety is unknown in high risk procedures such as polypectomy (Zuckerman et 
al, 2005). 
Thienopyridines (Ticlopidine, clopidogrel, prasugrel) are newer antiplatelet agents. The 
AHA recommends their use for a minimum of one month after placement of bare metal 
stents and one year for drug-eluting stents (King et al, 2008). Use of clopidogrel alone is not 
associated with an increased risk of post-polypectomy bleeding, however when combined 
with other antiplatelet agents, bleeding risk is increased (Singh et al, 2010). Due to the high 
rate of stent thrombosis associated with early cessation of dual antiplatelet (clopidogrel with 
aspirin), it is recommended that discontinuation should be avoided whenever possible 
(Iakovou et al, 2005). The ASGE recommends not discontinuing thienopyridines in patients 
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undergoing low-risk procedures including colonoscopy with or without biopsy (Anderson 
et al, 2009). In patients undergoing high-risk procedures including polypectomy, 
endoscopists are advised to consider the patient’s risk for thromboembolic phenomenon. If 
the patient is considered to have a low-risk condition, thienopyridines can be discontinued 
7-10 days before the procedure. Alternatively, procedures should be postponed until the 
time when thromboembolic risk is low (Anderson et al, 2009). In low-risk patients who 
discontinue thienopyridines, continuation of aspirin alone if they are on dual antiplatelet 
therapy or initiation of aspirin before procedure should be considered. This may decrease 
the risk of thromboembolic events without increasing the chance of developing significant 
bleeding. Thienopyridines should be restarted as soon as safely possible with consideration 
for their underlying indication and the procedure that has been performed (Anderson et al, 
2009). 
Glycoprotein IIb/IIIa receptor inhibitors (Epitifibatide, tirofiban, abciximab) are 
administered in some patients of acute coronary syndrome, however when elective 
colonoscopy is considered, patients are typically not taking one of these drugs. When 
patients require emergent colonoscopy for acute GI bleeding, these antiplatelet agents 
should be discontinued (Anderson et al, 2009).  
In patients who develop GI bleeding while on any anti-platelet agents, the decision to 
continue, stop, or reverse the antiplatelet effect should be tailored case-by-case, based on the 
severity of bleeding, the risk of thromboembolic events. A discussion with relevant 
consultants in this setting is advised. Diagnostic and therapeutic colonoscopy in the setting 
of acute lower GI bleeding while using antiplatelet agents has been deemed to be safe and is 
recommended (Anderson et al, 2009). 
 
Low risk procedure                                   High risk procedures 
Diagnostic(EGD, colonoscopy, flexible 
sigmoidoscopy) including biopsy 
Polypectomy 
Enteroscopy and diagnostic balloon-
assisted enteroscopy 
Therapeutic balloon-assisted enteroscopy 
ERCP without sphincterotomy Endoscopic homeostasis 
Enteral stent deployment(without dilation) Tumor ablation by any technique 
Capsule endoscopy Pneumatic or bougie dilation 
EUS without FNA Biliary or pancreatic sphincterotomy 
 PEG placement 
 EUS with FNA 
 Cystogastrostomy 
 Treatment of varices 
Table 2. Procedure risk for bleeding: adapted from ASGE guidelines (Anderson et al, 2009). 
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Low risk condition                                                High risk condition 
Uncomplicated or paroxysmal non-
valvular atrial fibrillation 
Atrial fibrillation associated with valvular 
heart disease, prosthetic valves, active 
congestive heart failure, left ventricular 
ejection fraction <35%, history of a 
thromboembolic event, hypertension, 
diabetes mellitus, or age>75 year 
Bio prosthetic valve 
Mechanical valve in any position and 
previous thromboembolic event 
Mechanical valve in aortic position Mechanical valve in mitral position 
Deep vein thrombosis Recent (<1 year) placed coronary stent 
 Acute coronary syndrome 
 
Non-stented percutaneous coronary 
intervention after myocardial infarction 
Table 3. Condition risk for thromboembolic event:  adapted from ASGE guidelines 
(Anderson et al, 2009). 
3.3 Management of anticoagulants 
The approach to the performance of colonoscopy in patients receiving anticoagulation 
agents (warfarin, heparin, low-molecular weight heparins) is another commonly 
encountered dilemma for the gastroenterologist. Using warfarin is not believed to increase 
the risk of significant bleeding in patients undergoing colonoscopy and other low-risk 
procedures (see table 2). The ASGE recommends continuation of warfarin for these 
procedures (Anderson et al, 2009). In high-risk procedures including polypectomy, there is 
an increased risk of bleeding (Hui et al, 2004). If patient is in a low thromboembolic risk 
group (see table 3), warfarin should be discontinued before a high-risk procedure, until the 
international normalized ratio (INR) is normal or nearly normal (Anderson et al, 2009). 
Vitamin K should be avoided since it delays the development of a therapeutic INR once 
warfarin is resumed. If patient is in a high thromboembolic risk group, bridging therapy 
(discontinue warfarin and administer heparin or LMWH) should be considered, however 
deferring the procedure to a time when the thromboembolic risk is low, is a better strategy 
whenever possible, depending on the degree of emergency of colonoscopy. The appropriate 
time to reinitiate warfarin and other anticoagulants after colonoscopy and other procedures 
is not clear. The ASGE recommends resumption of warfarin on the evening after procedure 
and heparin 2-6 hours after the procedure; however the risk of bleeding versus the risk of 
thromboembolic events should be weighed carefully and discussion with relevant 
consultants is suggested (Anderson et al, 2009).  
4. Special considerations for colonoscopy preparations 
4.1 Elderly 
Age does not, by itself, increase the risk to colonoscopy. Colonoscopy can be performed in 
octogenarians and older patients (Lagares-Garcia et al, 2001; Lukens et al, 2002). A 
significant problem encountered in the performance of colonoscopy in the elderly is the 
achievement of adequate bowel preparation. Dementia, cerebrovascular accident, diabetes 
mellitus, renal failure, chronic obstructive pulmonary disease, chronic constipation, use of 
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narcotics and tricyclic antidepressants are conditions that are associated with poor bowel 
preparation (Reilly & Walker, 2004; Ness et al; 2001; Taylor & Schubert, 2001).  All of these 
conditions are more common among elderly, however, even after eliminating all these 
independent predictors for inadequate bowel preparation, age still remains an independent 
risk factor for inadequate preparation, (Qureshi et al, 2000; Ure et al, 1995).  
Colonoscopy preparations often cause fecal incontinence in elderly patients, regardless of 
the type of bowel preparation, due to the large volume rectal output in a short time that 
these preparations induce. Thomson et al. found that approximately 25% of elderly 
experienced at least one episode of fecal incontinence during bowel preparation for 
colonoscopy (Thomson et al, 1996). 
The elderly are at increased risk of severe electrolyte imbalances from sodium phosphate 
containing colonoscopy preparations (Beloosesky et al, 2003; Gumurdulu et al, 2004). 
Elderly are also more likely to have comorbidities including renal failure, congestive heart 
failure, and cirrhosis that increase risk for electrolyte abnormalities and sudden change in 
intravascular volume. Additionally, the  elderly are more likely to be on  medications such 
as diuretics, nonsteroidal anti-inflammatory drugs(NSAIDs) and angiotensin converting 
enzyme inhibitors that are other potential causes for electrolyte abnormalities and change in 
intravascular volume when NaP is used (Anderson et al 2009; Ainley et al, 2005; Desmeules 
et al, 2003). Of interest, studies have suggested that the efficacy of sodium phosphate is 
similar to nonelderly adults and comparable with PEG (Thomson et al, 1996; Seinela et al, 
2003). 
Magnesium citrate causes electrolyte and fluid disturbances, especially in patients with 
renal dysfunction. Cases of hypermagnesemia have been reported in elderly patients after 
magnesium citrate preparations even without known kidney disease (Kontani et al, 2005; 
Schelling, 2000). 
Polyethylene glycol (PEG) does not, in general, cause fluid and electrolytes imbalance.  
However, a study done by Ho et al. showed that hypokalemia can occur after PEG 
preparation (Ho et al, 2010). Due to its large volume, PEG is contraindicated in patients with 
impaired swallowing function, (as seen in patients with stroke, dementia and Parkinson’s 
disease) all of which are more common among the elderly.  If colonoscopy is necessary in 
patients with these problems, a nasogastric tube can be inserted to administer the solution. 
However, it is possible that this approach does not decrease the risk of aspiration (Marschall 
et al, 1998).  
4.2 Female patients 
There is no data regarding the differences between men and women related to the success of 
bowel preparation for colonoscopy.  However, there are data regarding differences in 
completion of colonoscopy, procedure tolerance, difficulty of the procedure rated by 
colonoscopist, and detection of polyps. Completion of colonoscopy is less likely in females, 
especially if there is a history of hysterectomy (Church, 1994). Women have longer colons 
comparing to men, resulting in requirement for more time to perform colonoscopy, more 
discomfort to the patients, and increased technical difficulties in performance of the 
procedure. In a study performed by Saunders et al., female colons were 10 cm longer than 
men’s (P=0.005).  Technically difficult examinations were reported in 31% of women 
comparing to 16% of men (Saunders et al, 1996). Female gender was also an independent 
predictor of difficult colonoscopy in a study performed by Anderson (Anderson et al 2001).  
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In another study, looping of the colonoscope was more frequent (P = 0.0002) and the 
procedure was more painful (P = 0.0140) in women than in men (Shah et al, 2002). Detection 
of polyps and adenomas were lower in post-hysterectomy women compared to women 
without a hysterectomy (P= 0.008). In addition,  sigmoidoscopy was more painful (p < 
0.001), more difficult (p < 0.001), and less extensive (p < 0.0001) in this group, (Adams et al, 
2003). Women, especially of smaller stature are at increased risk of electrolyte abnormalities 
and renal injury from NaP-containing colonoscopy preparations. 
4.3 Pregnancy 
While the safety of colonoscopy and sigmoidoscopy has been established in the general 
population, colonoscopy during pregnancy has only been described in small case series and 
case reports.  The main two concerns in performing colonoscopy during pregnancy are 
maternal and fetal complications including usual complications of colonoscopy, premature 
delivery, low birth weight, fetal anomalies, placental abruption, fetal compression, 
medication toxicity, and stillbirth. In a retrospective study by Cappell et al. there were no 
maternal complications in 48 flexible sigmoidoscopies and 8 colonoscopies performed in 
pregnant women done during different trimesters (Cappell et al, 1996). Effects of the 
procedure on vital signs, including oxygen saturation, were clinically and statistically 
insignificant. Four fetal demises were reported in the study, but all 4 cases occurred in high-
risk pregnancies and at least 2 months after the procedure.  The group who underwent 
colonoscopy or sigmoidoscopy had similar outcomes in term of premature delivery, low 
birth weight, and cesarean section compared to aged-matched pregnant women who did 
not undergo endoscopy (Cappell et al, 1996). In another retrospective study from the same 
authors, there were no major maternal complications in 20 pregnant women undergoing 
colonoscopy. Mild, transient hypotension occurred in 2 patients (Cappell et al, 2010). The 
colonic preparations in their study included PEG, sodium phosphate, magnesium citrate, 
and water/saline enemas.  Anesthetics and sedative medications that were administered 
during colonoscopy included meperidine (category B drug during pregnancy), morphine 
(category C), fentanyl (category C), midazolam (category D), diazepam (category D), 
propofol (category B),  and thiopental (category C). Six patients underwent the procedure 
without anesthesia.  No fetal distress occurred during colonoscopy in the 6 patients who 
underwent fetal heart rate monitoring. In this study, also, there were no statistical 
differences between study group and the national average for pregnancy outcomes or a 
matched group in term of fetal outcomes including involuntary abortion, premature 
delivery, low birth weight, low Apgar score, cesarean section rate, congenital defects or 
stillbirth. Despite the estimate that 1500 colonoscopies are done annually during pregnancy 
in the United States, there are no prospective studies on colonoscopy in pregnancy (Cappell 
et al, 2010). Based on the aforementioned retrospective studies, it appears that both 
colonoscopy and sigmoidoscopy are safe in pregnancy. Even though PEG, NaP and 
magnesium citrate are category C drugs, they were administered for colonoscopy 
preparation without maternal or fetal complications (Cappell et al, 2010, although our group 
would strongly advise against the use of NaP containing preparations in these patients ). 
The diagnostic and therapeutic yield for colonoscopy or sigmoidoscopy is highest for rectal 
bleeding compared to abdominal pain, constipation, or diarrhea (Cappell et al, 1996; Cappell 
et al, 2010). The safest timing for colonoscopy or sigmoidoscopy during pregnancy is not 
known, however, sigmoidoscopies were performed almost equally in all three trimesters in 
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the first study while colonoscopies took place primarily in the second trimester in the 
second study by Cappell, (Cappell et al, 1996; Cappell et al, 2010). The ASGE recommends 
using PEG-ESL for colonoscopy preparation during pregnancy (Anderson et al, 2009). 
However, there are no controlled studies on the use and safety of PEG during pregnancy.  
The ASGE also suggests that colonoscopy should only be performed when the potential 
benefit outweighs the potential risks. ASGE guidelines for endoscopy in pregnant and 
lactating women published in 2005 recommend the following: procedures must always have 
a strong indication, defer to second trimester if possible, use category A or B sedative 
medications with the lowest effective dose, minimize procedure time, place pregnant 
patients with a left pelvic tilt or left lateral position. However, these recommendations are 
based on expert opinions rather than solid evidence based data (Qureshi et al, 2005).  
4.4 Low body weight 
Lower body mass index (BMI) has been associated with more difficult colonoscopy, lower 
cecal intubation rate, longer insertion time and more painful colonoscopy (Anderson et al, 
2001; Chung et al, 2007); however there are no data regarding if bowel preparation affects 
these findings. There are also no data to indicate that changes need to be made in the 
duration of the preparation, timing, and the amount of lavage solutions administered in the 
preparation for colonoscopy in patients with a low BMI. A pharmacokinetic analysis of 
liquid NaP colonoscopy preparation performed by our group has demonstrated that lower 
body weight individuals, particularly females, develop more pronounced 
hyperphosphatemia, acidosis, and decreased ionized calcium than normal weight or obese 
individuals when using these preparations (Ehrenpreis, 2009). 
4.5 Possible inflammatory bowel disease, ischemic colitis, or non-steroidal anti-
inflammatory drug-induced colitis 
Colonic mucosal changes that mimic grossly inflammatory bowel disease (IBD) changes or 
non-steroidal anti-inflammatory drug-induced colitis have been described with NaP 
preparations. Colonoscopic findings include aphthoid lesions, erosions and ulcers (Rejchrt et 
al, 2004).  Histologically, focal nonspecific inflammation, mucosal erosion, edema of the 
lamina propria, focal hemorrhage, and ulceration are seen (Rejchrt et al, 2004). In early 
studies, these mucosal changes were seen in more than 24% of patients who used NaP for 
bowel preparation (Zwas et al, 1996). More recent studies with a larger number of patients 
suggest that these changes occur in 3.3% of patients using these preparations (Rejchrt et al, 
2004). Due to these potential mucosal changes, AGSE discourages the use of NaP as a bowel 
cleanser in the initial colonoscopy in patients with a suspicion of IBD (Anderson et al, 2009).  
4.6 Diabetus mellitus 
Bowel preparation seems to be less effective in diabetic patients. In a study done by Taylor 
and Schubert, there was a significant difference in the quality of the bowel preparations with 
PEG ELS between diabetic and non-diabetic patients (p < 0.001) (Taylor & Schubert, 2001). 
Only 62% of the diabetic group had a preparation rated as good or better compared to 97% 
of the non-diabetic group (p < 0.001) (Taylor & Schubert, 2001). In this study, 9% of diabetic 
patients had a preparation rated as poor or futile, necessitating repeat colonoscopy 
compared to none in patients without diabetes (p < 0.01). Among the diabetic group, there 
was no difference in bowel preparation between patients on insulin and not on insulin, 
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those with hemoglobin A1c (Hb A1c) values >8% and those with values <8%, and those 
with and without diabetic neuropathy (Taylor & Schubert, 2001). In another study done by 
Oztur et al. using NaP as a bowel cleansing agent, optimal bowel cleansing was achieved in 
70% diabetics compared to 94%in the  non-diabetic group (P = 0.002).  Among the diabetic 
patients, there was a significant correlation between the quality of bowel cleansing and 
HbA1c level, duration of diabetes mellitus, and presence of late complications of diabetes (P 
<0.05) (Ozturk et al, 2010). Of note, both of the aforementioned studies were small. In a 
larger study of 362 patients, diabetes was independent predictor of poor bowel cleansing in 
patients using PEG as the agent for preparation (Chung et al, 2009).  
4.7 Colonoscopy preparation in children  
Colonoscopy is relatively uncommon in pediatric population. There are no uniform 
protocols or national guidelines for colonoscopy preparation. PEG ESL is the most common 
bowel cleansing agent used in pediatrics.  However the large volume and potentially 
unpleasant taste of these solutions has been a major limitation in their use. Placement of a 
nasogastric tube has been used in some studies. In one study, PEG ESL was better tolerated 
than total gut irrigation using normal saline with added potassium.  Both regimens 
demonstrated equivalency for side effects and efficacy (Chattopadhyay et al, 2004). PEG-
3350 without electrolytes (Miralax) has been increasingly used for bowel cleansing for 
colonoscopy in children.  PEG 3350 solution was first studied with a 4 day regimen, 
showing safety, efficacy, and tolerability in children (Safder et al, 2008). A subsequent study 
showed that even a one day regimen of PEG-3350 is effective in 93% of children (Adamiak et 
al, 2010). 
Bisacodyl with NaP enemas has been tested in different studies with a high rate of 
compliance and bowel preparation. In a study of 98 children between 30 months to 12 years 
of age, the compliance of the bisacodyl with NaP enema group was 100%, compared to 88% 
in PEG group. Good to excellent bowel preparation achieved in 95% in bisacodyl with NaP 
enema group compared to 88% in PEG ESL group (Shaoul & Haloon L, 2007).  However, 
another study of 70 children did not show the same results. PEG ESL was superior for bowel 
cleansing (p < 0.0001) but was inferior to NaP  enema in terms of tolerance and compliance 
(p < 0.003) (Dahshan et al, 1999).  
Oral NaP was studied for use as a bowel preparation for pediatric colonoscopy.  One study 
showed that NaP was superior to PEG-based solutions in term of tolerance, compliance and 
bowel cleansing (Gremse et al, 1996). However, there is potential risk of electrolytes and 
fluid disturbance in NaP. Our group recommends avoidance of these preparations in 
children. 
Magnesium citrate was used combined with senna (X-prep) in some pediatric patients. This 
combination was shown to be superior to bisacodyl combined with a NaP enema (p < 
0.0001), but inferior to PEG ELS (p < 0.075) in term of quality of bowel cleansing (Dahshan et 
al, 1999). Overall tolerance and compliance were significantly better than PEG ELS (p < 
0.003) (Dahshan et al, 1999). In another study, magnesium citrate was used with bisacodyl 
and demonstrated to be superior to NaP (P = .013) in term of bowel cleansing. Both 
regimens were equivalent for tolerance and compliance (El-Baba et al, 2006). In a third study 
of  48 children, magnesium citrate was used with a NaP enema for a 3 days protocol and 
compared to a one day regimen of oral NaP alone (Sabri et al, 2008). Bowel cleansing was 
similar in two groups (71% good or excellent) and side effects were similar except nausea 
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which was more frequent in NaP.  However, patients stated that they were more willing to 
repeat NaP alone compared to the combination regimen (77%vs 32%, respectively, P < 0.006) 
(Sabri et al, 2008).  
5. Conclusion 
The choice of bowel preparation for colonoscopy should be individualized after thorough 
patient screening. Next generation lower volume regimens have been developed that are 
well tolerated and preferred by the patients over traditional larger volume bowel 
preparations. NaP preparations are generally more effective and better tolerated than PEG-
ELSs. However there is increasing concern regarding toxicity of NaP formulations, 
especially in light of the availability of newer, potentially better tolerated preparations.  
6. Future research 
There is ongoing research to develop safe bowel preparation regimens that provide good 
bowel cleansing along with better patient tolerability and low side effect profile. Further 
research is also needed for effect of bowel preparations in the elderly, pregnant women and 
children as well as in patients with significant morbidities. Gender based risk of adverse 
effects is a newly studied phenomenon that requires additional study. 
7. References 
Adamiak, T; Altaf, M; Jensen, M.K; Sultan, M; Ramprasad, J; Ciecierega, T; Sherry, K & 
Miranda, A (2010). One-day bowel preparation with polyethylene glycol 3350: an 
effective regimen for colonoscopy in children. Gastrointest Endosc, Vol.71, No.3, 
(Mar 2010), pp.573-7, ISSN: 0016-5107. 
Adams, C; Cardwell, C; Cook, C; Edwards, R; Atkin, W.S & Morton, D.G (2003). Effect of 
hysterectomy status on polyp detection rates at screening flexible sigmoidoscopy. 
Gastrointest Endosc, Vol.57, No.7, (Jun 2003), pp.848-53, ISSN: 0016-5107. 
Ainley, E.J; Winwood, P.J & Begley, J.P (2005). Measurement of serum electrolytes and 
phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. 
Dig Dis Sci, Vol.50, No.7, (2005), pp.1319-23, ISSN: 0163-2116. 
American Society for Gastrointestinal Endoscopy. (2000).  Appropriate use of 
gastrointestinal endoscopy. Gastrointestinal endoscopy. Vol.52, No.6, (2000), pp.831-
837, ISSN: 0016-5107. 
Anderson, J.C; Messina, C.R; Cohn, W; Gottfried, E; Ingber, S; Bernstein, G; Coman, E & 
Polito, J (2001). Factors predictive of difficult colonoscopy. Gastrointest Endosc, 
Vol.54, No.5, (Nov 2001), pp.558-62, ISSN: 0016-5107. 
Anderson, M.A; Ben-Menachem, T; Gan, S.I; Appalaneni, V; Banerjee, S; Cash, B.D; Fisher, 
L; Harrison, M.E; Fanelli, R.D; Fukami, N; Ikenberry, S.O; Jain, R; Khan, K; Krinsky, 
M.L; Lichtenstein, D.R; Maple, J.T; Shen, B; Strohmeyer, L; Baron, T & Dominitz, 
J.A (2009). ASGE Standards of Practice Committee. Management of antithrombotic 
agents for endoscopic procedures. Gastrointest Endosc, Vol.70, No.6, (Dec 2009), 
pp.1060-70, ISSN: 0016-5107. 
Aronchick, CA; Lipshutz, WH; Wright, SH; Dufrayne, F & Bergman, G. (2000).A novel 
tableted purgative for colonoscopic preparation: efficacy and safety comparisons 
www.intechopen.com
 
Endoscopic Procedures in Colon and Rectum 
 
34
with Colyte and Fleet Phospho-Soda. Gastrointest Endosc,Vol.52, No.3, (Sep 
2000),pp.346-52, ISSN: 0016-5107. 
Bac, D.J; van Blankenstein, M; de Marie, S & Fieren, M.W (1994). Peritonitis following 
endoscopic polypectomy in a peritoneal dialysis patient: the need for antibiotic 
prophylaxis. Infection, Vol.22, No.3, (May-Jun 1994), pp.220-1, ISSN: 0163-4453 
Banerjee, S; Shen, B; Baron, T.H; Nelson, D.B; Anderson, M.A; Cash, B.D; Dominitz, J.A; 
Gan, S.I; Harrison, M.E; Ikenberry, S.O; Jagannath, S.B; Lichtenstein, D; Fanelli, 
R.D; Lee, K; van Guilder, T & Stewart, L.E (2008). ASGE STANDARDS OF 
PRACTICE COMMITTEE.  Antibiotic prophylaxis for GI endoscopy. Gastrointest 
Endosc, Vol. 67, No. 6,  (May 2008), pp. 791-8, ISSN: 0016-5107. 
Belsey, J; Epstein, O & Heresbach, D. (2007).Systematic review: oral bowel preparation for 
colonoscopy. Aliment Pharmacol Ther,Vol.25,(2007),pp.373-84, ISSN: 0269-2813. 
Beloosesky, Y; Grinblat, J; Weiss, A; Grosman, B; Gafter, U & Chagnac, A (2003). Electrolyte 
disorders following oral sodium phosphate administration for bowel cleansing in 
elderly patients. Arch Intern Med, Vol.163, No.7, (2003), pp.803-8, ISSN: 0003-9926 
(print); 1538-3679 (online). 
Bhanji, S; Williams, B; Sheller, B; Elwood, T & Mancl, L (2002). Transient bacteremia induced 
by toothbrushing a comparison of the Sonicare toothbrush with a conventional 
toothbrush. Pediatr Dent, Vol.24, No.4, (Jul-Aug 2002), pp.295-9, ISSN: 0164-1263. 
Calderwood, A.H. & Jacobson, B.C. (2010). Comprehensive validation of the Boston Bowel 
Preparation Scale. Gastrointest Endosc, Vol. 72, No. 4, (October 2010), pp. 682-92, 
ISSN: 0016-5107 
Cappell, M.S; Colon, V.J & Sidhom, O.A (1996). A study at 10 medical centers of the safety 
and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy 
with follow-up of fetal outcome and with comparison to control groups. Dig Dis 
Sci, Vol.41, No.12, (Dec 1996), pp.2353-61, ISSN: 0163-2116. 
Cappell, M.S; Fox, S.R & Gorrepati, N (2010).  Safety and efficacy of colonoscopy during 
pregnancy: an analysis of pregnancy outcome in 20 patients. J Reprod Med, Vol.55, 
No.3-4, (Mar-Apr 2010), pp.115-23, ISSN: 0024-7758. 
Chang, KJ; Erickson, RA; Schandler, S; Coye, T & Moody, C. (1991). Per-rectal pulsed 
irrigation versus per-oral colonic lavage for colonoscopy preparation: a 
randomized, controlled trial. Gastrointest Endosc, Vol.37, No.4,(Jul-Aug 1991) 
pp.444-8, ISSN: 0016-5107. 
Chattopadhyay, A; Prakash, B; Vepakomma, D; Nagendhar, Y & Vijayakumar (2004). A 
prospective comparison of two regimes of bowel preparation for pediatric 
colorectal procedures: normal saline with added potassium vs. polyethylene glycol. 
Pediatr Surg Int, Vol.20, No.2, (Feb 2004), pp.127-9, ISSN: 0179-0358 (print); 1437-
9813 (online). 
Chung, Y.W; Han, D.S; Yoo, K.S & Park, C.K (2007). Patient factors predictive of pain and 
difficulty during sedation-free colonoscopy: a prospective study in Korea. Dig 
Liver Dis, Vol.39, No.9, (Sep 2007), pp.872-6, ISSN: 1590-8658 (Print); 1878-3562 
(online). 
Chung, Y.W; Han, D.S; Park, K.H; Kim, K.O; Park, C.H; Hahn, T; Yoo, K.S; Park, S.H; Kim, 
J.H & Park, C.K (2009). Patient factors predictive of inadequate bowel preparation 
using polyethylene glycol: a prospective study in Korea. J Clin Gastroenterol, 
Vol.43, No.5, (May-Jun 2009), pp.448-52, ISSN: 0192-0790 (print); 1539-2031 (online). 
www.intechopen.com
 
Preparing for Colonoscopy 
 
35 
Church JM (1994). Complete colonoscopy: how often? And if not, why not? Am J 
Gastroenterol, Vol.89, No.4, (Apr 1994), pp.556-60, ISSN: 0002-9270 9print); 1572-
0241 (online). 
Church, JM. (1998).Effectiveness of polyethylene glycol antegrade gut lavage bowel 
preparation for colonoscopy. Timing is the key! Dis Colon Rectum, Vol.41,(1998), 
pp.1223-5, ISSN: 00123706. 
Clark, L.E & DiPalma, J.A. (2004). Safety issues regarding colonic cleansing for diagnostic 
and surgical procedures. Drug Saf, Vol. 27, No. 15, (2004), pp. 1235-42. ISSN: 0114-
5916 
Cornelius, L.K; Reddix, R.N & Jr, Carpenter, J.L (2003). Periprosthetic knee joint infection 
following colonoscopy. A case report. J Bone Joint Surg Am, Vol.85-A, No.12, (Dec 
2003), pp.2434-6, ISSN: 0021-9355. 
Dahshan, A; Lin, C.H; Peters, J; Thomas, R & Tolia, V (1999). A randomized, prospective 
study to evaluate the efficacy and acceptance of three bowel preparations for 
colonoscopy in children. Am J Gastroenterol, Vol.94, No.12, (Dec 1999), pp.3497-
501, ISSN: 0002-9270 (print); 1572-0241 (online). 
Delegge, M & Kaplan, R. (2005). Efficacy of bowel preparation with the use of a 
prepackaged, low fibre diet with a low sodium, magnesium citrate cathartic vs. a 
clear liquid diet with a standard sodium phosphate cathartic. Aliment Pharmacol 
Ther, Vol.21, No.12, (Jun 2005), pp.1491-5, ISSN: 0269-2813. 
Desmeules, S; Bergeron, M.J & Isenring, P (2003). Acute phosphate nephropathy and renal 
failure. N Engl J Med, Vol.309, (2003), pp.1006, ISSN: 0028-4793 (print); 1533-4406 
(online).  
DiPalma, JA & Marshall, JB. (1990).Comparison of a new sulfate-free polyethylene glycol 
electrolyte lavage solution versus a standard solution for colonoscopy cleansing. 
Gastrointest Endosc,Vol.36, No.3, (May-Jun 1990), pp.285-9, ISSN: 0016-5107. 
DiPalma, JA; Wolff, BG; Meagher, A & Cleveland, M. (2003).Comparison of reduced volume 
versus four liters sulfate-free electrolyte lavage solutions for colonoscopy colon 
cleansing. Am J Gastroenterol,Vol.98, No.10, (Oct 2003), pp.2187-91, ISN: 0002-9270.  
Ehrenpreis, ED; Nogueras, JJ; Botoman, VA; Bonner, GF; Zaitman, D & Secrest, KM. (1996). 
Serum electrolyte abnormalities secondary to Fleet’s Phospho-Soda colonoscopy 
prep. Surg Endosc, Vol.10, (1996),pp.1022-24, ISSN: 0930-2794. 
Ehrenpreis, E.D.; Wieland, J.M.; Cabral, J.; Estevez, V.; Zaitman, D. & Secrest, K. (1997). 
Symptomatic hypocalcemia, hypomagnesemia, and hyperphosphatemia secondary 
to Fleet’s Phospho-Soda colonoscopy preparation in a patient with a jejunoileal 
bypass. Dig Dis Sci. Vol. 42, No. 4, (April 1997), pp. 858-60, ISSN: 0163-2116 
Ehrenpreis, E.D. (2009). Increased serum phosphate levels and calcium fluxes are seen in 
smaller individuals after a single dose of sodium phosphate colon cleansing 
solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. Vol. 29, No. 11, (June 
2009), pp. 1202-11, ISSN: 1365-2036 
El-Baba, M.F; Padilla, M; Houston, C; Madani, S; Lin, C.H; Thomas, R & Tolia, V (2006). A 
prospective study comparing oral sodium phosphate solution to a bowel cleansing 
preparation with nutrition food package in children. J Pediatr Gastroenterol Nutr, 
Vol.42, No.2, (Feb 2006), pp.174-7, ISSN: 0277-2116 9print); 1536-4801 (online). 
Ell, C; Fischbach, W; Bronisch, HJ; Dertinger, S; Layer, P; Rünzi, M; Schneider, T; Kachel, G; 
Grüger, J; Köllinger, M; Nagell, W; Goerg, KJ; Wanitschke, R & Gruss, HJ. 
www.intechopen.com
 
Endoscopic Procedures in Colon and Rectum 
 
36
(2008).Randomized trial of low-volume PEG solution versus standard PEG + 
electrolytes for bowel cleansing before colonoscopy. Am J Gastroenterol,Vol.103, 
No.4, (Apr 2008), pp.883-93, ISN: 0002-9270.  
El Sayed, AM; Kanafani, ZA; Mourad, FH; Soweid, AM; Barada, KA; Adorian, CS, 
Nasreddine, WA & Sharara, AI. (2003). A randomized single-blind trial of whole 
versus split-dose polyethylene glycol-electrolyte solution for colonoscopy 
preparation. Gastrointest Endosc,Vol.58, (2003), pp.36-40, ISSN: 0016-5107. 
Food and Drug Administration. (December, 2008). Oral Sodium Phosphate (OSP) Products 
for Bowel Cleansing (marketed as  Visicol and OsmoPrep, and oral sodium 
phosphate products available without a prescription). In: Food and Drug 
Administration, 3/15/2011, available from 
 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa
tientsandProviders/ucm103354.htm 
Froehlich, F; Wietlisbach, V; Gonvers, JJ; Burnand, B & Vader, JP. (2005).Impact of colonic 
cleansing on quality and diagnostic yield of colonoscopy: the European Panel of 
Appropriateness of Gastrointestinal Endoscopy European multicenter study. 
Gastrointest Endosc,Vol.61, No.3, (Mar 2005), pp.378-84, ISSN: 0016-5107. 
Frommer, D. (1997). Cleansing ability and tolerance of three bowel preparations for 
colonoscopy. Dis Colon Rectum,Vol.40, (1997), pp.100-4, ISSN: 00123706. 
Goldman, G.D; Miller, S.A; Furman, D.S; et al (1985). Does bacteremia occur during flexible 
sigmoidoscopy? Am J Gastroenterol, Vol.80, (1985), pp.621-3, ISSN: 0002-9270. 
Gremse, D.A; Sacks, A.I & Raines, S (1996). Comparison of oral sodium phosphate to 
polyethylene glycol-based solution for bowel preparation for colonoscopy in 
children. J Pediatr Gastroenterol Nutr, Vol.23, No.5, (Dec 1996), pp.586-90, ISSN: 
0277-2116 (print); 1536-4801 (online). 
Grossman, E.B; Maranino, A.N; Zamora, D.C; et al (2010). Antiplatelet medications increase 
the risk of post-polypectomy bleeding. Gastrointest Endosc, Vol.71, (2010), 
pp.AB138, ISSN: 0016-5107. 
Gumurdulu, Y; Serin, E; Ozer, B; Gokcel, A & Boyacioglu, S (2004). Age as a predictor of 
hyperphosphatemia after oral phosphosoda administration for colon preparation. J 
Gastroenterol Hepatol, Vol.19, No.1, (2004), pp.68-72, ISSN: 0815-9319 9print); 1440-
1746 (online). 
Harewood, GC; Sharma, VK & de Garmo, P. (2003). Impact of colonoscopy preparation 
quality on detection of suspected colonic neoplasia. Gastrointest Endosc,Vol.58, 
No.1, (Jul 2003), pp.76-9,. ISSN: 0016-5107. 
Ho, J.M; Juurlink, D.N & Cavalcanti, R.B (2010). Hypokalemia following polyethylene 
glycol-based bowel preparation for colonoscopy in older hospitalized patients with 
significant comorbidities. Ann Pharmacother, Vol.44, No.3, (Mar 2010), pp.466-70, 
ISSN: 1060-0280 (print); 1542-6270 (online). 
Hui, A.J; Wong, R.M; Ching, J.Y; Hung, L.C, Chung, S.C & Sung, J.J (2004). Risk of 
colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: 
analysis of 1657 cases. Gastrointest Endosc, Vol.59, No.1, (Jan 2004), pp.44-8, ISSN: 
0016-5107. 
Iakovou, I; Schmidt, T; Bonizzoni, E; Ge, L; Sangiorgi, G.M; Stankovic, G; Airoldi, F; Chieffo, 
A; Montorfano, M; Carlino, M; Michev, I; Corvaja, N; Briguori, C; Gerckens, U; 
Grube, E & Colombo, A (2005). Incidence, predictors, and outcome of thrombosis 
www.intechopen.com
 
Preparing for Colonoscopy 
 
37 
after successful implantation of drug-eluting stents. JAMA, Vol.293, No.17, (May 
2005), pp.2126-30, ISSN: 00987484 (print); 15383598 (online). 
Iida, Y.; Miura, S.; Asada, Y.; Fukuoka, K.; Toya, D.; Tanaka, N. & Fujisawa, M. (1992). 
Bowel preparation for the total colonoscopy by 2000 ml of balanced lavage solution 
(GoLytely) and sennoside. Gastroenterol Jpn, Vol. 27, No. 6, (December 1992), pp. 
728-33, ISSN: 0944-1174 
Johanson, JF; Popp, JW Jr; Cohen, LB; Lottes, SR; Forbes, WP; Walker, K; Carter, E;, Zhang, B 
& Rose, M. (2007).A randomized, multicenter study comparing the safety and 
efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus 
bisacodyl tablets for colon cleansing. Am J Gastroenterol,Vol.102, No.10, (Oct 2007), 
pp.2238-46, ISN: 0002-9270.  
Kazarian, ES; Carreira, FS; Toribara, NW & Denberg, TD. (2008).Colonoscopy completion in 
a large safety net health care system. Clin Gastroenterol Hepatol,Vol.6, No.4, (April 
2008), pp.377-8, ISSN: 1542-3565. 
King, S.B 3rd; Smith, S.C Jr; Hirshfeld, J.W Jr; Jacobs, A.K; Morrison, D.A; Williams, D.O; 
Feldman, T.E; Kern, M.J; O'Neill, W.W; Schaff, H.V & Whitlow, P.L; 
ACC/AHA/SCAI, Adams, C.D; Anderson, J.L; Buller, C.E; Creager, M.A; Ettinger, 
S.M; Halperin, J.L; Hunt, S.A; Krumholz, H.M; Kushner, F.G; Lytle, B.W; 
Nishimura, R; Page, R.L; Riegel, B; Tarkington, L.G & Yancy, C.W (2008). 2007 
focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous 
coronary intervention: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008 Jan 
15;51(2):172-209. ISSN: 0735-1097 
Kontani, M; Hara, A; Ohta, S & Ikeda, T (2005). Hypermagnesaemia induced by massive 
cathartic ingestion in an elderly woman without pre-existing renal dysfunction. 
Intern Med, Vol.44, (2005), pp.448, ISSN: 0918-2918 (Print); 1349-7235 (online).  
Lagares-Garcia, J.A; Kurek, S; Collier, B; Diaz, F; Schilli, R; Richey, J & Moore, R.A (2001). 
Colonoscopy in octogenarians and older patients. Surg Endosc, Vol.15, No.3, (Mar 
2001), pp.262-5, ISSN: 1432-2218 (online). 
Lai, E.J.; Calderwood, A.H.; Doros, G.; Fix, O.K. & Jacobson, B.C. (2009).  The Boston bowel 
preparation scale: a valid and reliable instrument for colonoscopy-oriented 
research. Gastrointest Endosc, Vol. 69, No. 3, (March 2009), pp. 620-25, ISSN: 0016-
5107 
Levin, B; Lieberman, DA; McFarland, B; Andrews, KS; Brooks, D; Bond, J; Dash, C; 
Giardiello, FM; Glick, S; Johnson, D; Johnson, CD; Levin, TR; Pickhardt, PJ; Rex, 
DK; Smith, RA; Thorson, A; Winawer, SJ; American Cancer Society Colorectal 
Cancer Advisory Group; US Multi-Society Task Force & American College of 
Radiology Colon Cancer Committee. (2008). Screening and surveillance for the 
early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline 
from the American Cancer Society, the US Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radiology.CA Cancer J Clin,Vol.58, No.3, 
(May-Jun 2008),pp.130-60, Online ISSN: 1542-4863. 
Levy, M.J; Norton, I.D; Clain, J.E; et al (2007). Prospective study of bacteremia and 
complications with EUS FNA of rectal and perirectal lesions. Clin Gastroenterol 
Hepatol, Vol.5, (2007), pp.684-9, ISSN: 1542-3565. 
www.intechopen.com
 
Endoscopic Procedures in Colon and Rectum 
 
38
Lichtenstein, G. (2009).Bowel preparations for colonoscopy: a review. Am J Health Syst 
Pharm,Vol.66, No.1, (Jan 2009), pp.27-37, ISSN: 1079-2082. 
Li, P.K; Szeto, C.C; Piraino, B; Bernardini, J; Figueiredo, A.E; Gupta, A; Johnson, D.W; 
Kuijper, E.J; Lye, W.C; Salzer, W; Schaefer, F & Struijk, D.G (2010). Peritoneal 
dialysis-related infections recommendations: 2010 update. Perit Dial Int, Vol.30, 
No.4, (Jul-Aug 2010), pp.393-423, ISSN: 0896-8608 (print); 1718-4304 (online). 
Llach, J; Elizalde, J.I; Bordas, J.M; et al (1999). Prospective assessment of the risk of 
bacteremia in cirrhotic patients undergoing lower intestinal endoscopy. 
Gastrointest Endosc, Vol.49, (1999), pp.214-7, ISSN: 0016-5107. 
Lockhart, P.B; Brennan, M.T; Sasser, H.C; Fox, P.C; Paster, B.J & Bahrani-Mougeot, F.K 
(2008). Bacteremia associated with tooth brushing and dental extraction. 
Circulation. Vol.117, No.24, (Jun 2008), pp.3118-25, ISSN: 0009-7322. 
Lukens, F.J; Loeb, D.S; Machicao, V.I; Achem, S.R & Picco, M.F (2002). Colonoscopy in 
octogenarians: a prospective outpatient study. Am J Gastroenterol, Vol.97, No.7, 
(2002), pp.1722-5, ISSN: 0002-9270 (print); 1572-0241(online). 
Marschall, H.U & Bartels F (1998). Life-threatening complications of nasogastric 
administration of polyethylene glycol-electrolyte solution (Golytely) for bowel 
cleansing. Gastrointest Endosc, Vol.47, No.5, (1998), pp.408-10, ISSN: 0016-5107. 
Nelson, D.B (2003). Infectious disease complications of GI endoscopy: part I, endogenous 
infections. Gastrointest Endosc, Vol.57, (2003), pp.546-56, ISSN: 0016-5107. 
Ness, R.M; Manam, R; Hoen, H & Chalasani, N (2001). Predictors of inadequate bowel 
preparation for colonoscopy. Am J Gastroenterol, Vol.96, (2001), pp.1797, ISSN: 
0002-9270 (print); 1572-0241 (online). 
Ozturk, N.A; Gokturk, H.S; Demir, M; Unler, G.K; Gur, G & Yilmaz, U (2010). Efficacy and 
safety of sodium phosphate for colon cleansing in type 2 diabetes mellitus. South 
Med J, Vol.103, No.11, (Nov 2010), pp.1097-102, ISSN: 0038-4348 (print); 1541-8243 
(online). 
Parakkal, D. & Ehrenpreis E.D. (2010). Calcium phosphate nephropathy from colonoscopy 
preparations: effect of body weight. Am J Gastroenterol, Vol.105, No.3, (Mar 2010), 
pp. 705, ISSN: 0002-9270 
Pelham, R.W.; Russell, R.G.; Padgett, E.L.; Reno, F.E. & Cleveland, M. (2009). Safety of oral 
sulfates in rats and dogs contrasted with phosphate-induced nephropathy in rats. 
Int J Toxicol, Vol. 28, No. 2, (March-April 2009), pp.99-112, ISSN: 1091-5818 
Piraino, B; Bailie, G.R; Bernardini, J; Boeschoten, E; Gupta, A; Holmes, C; Kuijper, E.J; Li, 
P.K; Lye, W.C; Mujais, S; Paterson, D.L; Fontan, M.P; Ramos, A; Schaefer, F & 
Uttley, L; ISPD Ad Hoc Advisory Committee (2005). Peritoneal dialysis-related 
infections recommendations: 2005 update. Perit Dial Int, Vol.25, No.2, (Mar-Apr 
2005), pp.107-31, ISSN: 0896-8608 (print); 1718-4304 (online). 
Qureshi, A; Ismail, S; Azmi, A; Murugan, P & Husin, M (2000). Poor bowel preparation in 
patients undergoing colonoscopy. Med J Malaysia, Vol.55, No.2, (Jun 2000), pp.246-
8, ISSN: 0300-5283. 
Qureshi, W.A; Rajan, E; Adler, D.G; Davila, R.E; Hirota, W.K; Jacobson, B.C; Leighton, J.A; 
Zuckerman, M.J; Hambrick, R.D; Fanelli, R.D; Baron, T & Faigel, D.O (2005); 
American Society for Gastrointestinal Endoscopy. ASGE Guideline: Guidelines for 
endoscopy in pregnant and lactating women. Gastrointest Endosc, Vol.61, No.3, 
(Mar 2005), pp.357-62, ISSN: 0016-5107. 
www.intechopen.com
 
Preparing for Colonoscopy 
 
39 
Ray, S.M; Piraino, B & Holley, J (1990). Peritonitis following colonoscopy in a peritoneal 
dialysis patient. Perit Dial Int, Vol.10, No.1, (1990), pp.97-8, ISSN: 0896-8608; 1718-
4304 (online). 
Reilly, T & Walker, G (2004). Reasons for poor colonic preparation with inpatients. 
Gastroenterol Nurs, Vol.27, No.3, (May-Jun 2004), pp.115-7, ISSN: 1042-895X; 1538-
9766 (online). 
Rejchrt, S.; Bures, J.; Siroký, M.; Kopácová, M.; Slezák, L. & Langr, F. (2004). A prospective, 
observational study of colonic mucosal abnormalities associated with orally 
administered sodium phosphate for colon cleansing before colonoscopy. 
Gastrointest Endosc, Vol. 59, No. 6, (May 2004), pp.651-4, ISSN: 0016-5107. 
Rex, DK; Imperiale, TF; Latinovich, DR & Bratcher, LL. (2002).Impact of bowel preparation 
on efficiency and cost of colonoscopy. Am J Gastroenterol,Vol.97, No.7, (Jul 2002), 
pp.1696-700, ISN: 0002-9270.  
A)Rex, D.K.; Petrini, J.L.; Baron, T.H.; Chak, A.; Cohen, J.; Deal, S.E.; Hoffman, B.; Jacobson, 
B.C.; Mergener, K.; Petersen, B.T.; Safdi, M.A.; Faigel, D.O.; Pike, I.M. & 
ASGE/ACG Taskforce on Quality in Endoscopy. (2006). Quality indicators for 
colonoscopy. Am J Gastroenterol, Vol. 101, No. 4, (April 2006), pp. 873–85, ISN: 0002-
9270 
B)Rex, DK; Schwartz, H; Goldstein, M; Popp, J; Katz, S; Barish, C; Karlstadt, RG; Rose, M; 
Walker, K; Lottes, S; Ettinger, N & Zhang, B. (2006).Safety and colon-cleansing 
efficacy of a new residue-free formulation of sodium phosphate tablets. Am J 
Gastroenterol,Vol.101, No.11, (Nov 2006), pp.2594-604, ISN: 0002-9270.  
Rex, DK; Johnson, DA; Anderson, JC; Schoenfeld, PS; Burke, CA; Inadomi, JM & American 
College of Gastroenterology. (2009).American College of Gastroenterology 
guidelines for colorectal cancer screening 2009 [corrected]. Am J 
Gastroenterol,Vol.104, No.3,( Mar 2009),pp.739-50, ISSN: 0002-9270 
Rex, DK; Di Palma, JA; Rodriguez, R; McGowan, J & Cleveland, M. (2010).A randomized 
clinical study comparing reduced-volume oral sulfate solution with standard 4-liter 
sulfate-free electrolyte lavage solution as preparation for colonoscopy. Gastrointest 
Endosc,Vol.72, (2010), pp.328-336, ISSN: 0016-5107. 
Sabri, M; Di Lorenzo, C; Henderson, W; Thompson, W; Barksdale, E Jr & Khan, S (2008). 
Colon cleansing with oral sodium phosphate in adolescents: dose, efficacy, 
acceptability, and safety. Am J Gastroenterol, Vol.103, No.6, (Jun 2008), pp.1533-9, 
ISSN: 0002-9270 (print); 1572-0241 (online). 
Safder, S; Demintieva, Y; Rewalt, M & Elitsur, Y (2008). Stool consistency and stool 
frequency are excellent clinical markers for adequate colon preparation after 
polyethylene glycol 3350 cleansing protocol: a prospective clinical study in 
children. Gastrointest Endosc, Vol.68, No.6, (Dec 2008), pp.1131-5, ISSN: 0016-5107. 
Saunders, B.P; Fukumoto, M; Halligan, S; Jobling, C; Moussa, M.E; Bartram, C.I & Williams, 
C.B (1996). Why is colonoscopy more difficult in women? Gastrointest Endosc, 
Vol.43, No.2 pt 1, (Feb 1996), pp.124-6, ISSN: 0016-5107. 
Schelling, J.R. (2000). Fatal hypermagnesemia. Clin Nephrol, Vol. 53, No. 1, (January 2000), 
pp. 61-5, ISSN: 0301-0430. 
Seeff, L.C; Richards, T.B; Shapiro, J.A; et al (2004). How many endoscopies are performed for 
colorectal cancer screening? Results from CDC’s survey of endoscopic capacity. 
Gastroenterology, Vol.127, (2004), pp.1670-7, ISSN: 0016-5085. 
www.intechopen.com
 
Endoscopic Procedures in Colon and Rectum 
 
40
Seinela, L; Pehkonen, E; Laasanen, T & Ahvenainen, J (2003). Bowel preparation for 
colonoscopy in very old patients: a randomized prospective trial comparing oral 
sodium phosphate and polyethylene glycol electrolyte lavage solution. Scand J 
Gastroenterol, Vol.38, No.2, (2003), pp.216-20, ISSN: 0036-5521 (Print); 1502-7708 
(online). 
Shah, S.G; Brooker, J.C; Thapar, C; Williams, C.B & Saunders, B.P (2002). Patient pain during 
colonoscopy: an analysis using real-time magnetic endoscope imaging. Endoscopy, 
Vol.34, No.6, (Jun 2002), pp.435-40, ISSN: 0013-726X (Print); 1438-8812 (online). 
Shaoul, R & Haloon, L (2007). An assessment of bisacodyl-based bowel preparation for 
colonoscopy in children. J Gastroenterol, Vol.42, No.1, (Jan 2007), pp.26-8, ISSN: 
0944-1174 (Print); 1435-5922 (online). 
Sharma, VK; Chockalingham, SK; Ugheoke, EA; Kapur, A; Ling, PH; Vasudeva, R &  
Howden, CW. (1998).Prospective, randomized, controlled comparison of the use of 
polyethylene glycol electrolyte lavage solution in four-liter versus two-liter 
volumes and pretreatment with either magnesium citrate or bisacodyl for 
colonoscopy preparation. Gastrointest Endosc,Vol.47, No.2, (Feb 1998), pp.167-71, 
ISSN: 0016-5107. 
Singh, M; Mehta, N; Murthy, U.K; Kaul, V; Arif, A & Newman, N (2010). Postpolypectomy 
bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel 
therapy. Gastrointest Endosc, Vol.71, No.6, (May 2010), pp.998-1005, ISSN: 0016-
5107. 
Tan, JJ & Tjandra, JJ. (2006).Which is the optimal bowel preparation for colonoscopy: a meta-
analysis. Colorectal Dis,Vol.8, (2006), pp.247-58, ISSN 1462-8910. 
Taylor, C & Schubert, M.L (2001). Decreased efficacy of polyethylene glycol lavage solution 
(golytely) in the preparation of diabetic patients for outpatient colonoscopy: a 
prospective and blinded study. Am J Gastroenterol, Vol.96, No.3, (Mar 2001), 
pp.710-4, ISSN: 0002-9270 (print); 1572-0241 (online). 
Thomas-Gibson, S; Rogers, P; Cooper, S; Man, R; Rutter, MD; Suzuki, N; Swain, D; 
Thuraisingam, A & Atkin, W. (2006).Judgement of the quality of bowel preparation 
at screening flexible sigmoidoscopy is associated with variability in adenoma 
detection rates. Endoscopy,Vol.38, No.5, (May 2006), pp.456-60, ISSN: 0013726X. 
Thomson, A; Naidoo, P & Crotty, B (1996). Bowel preparation for colonoscopy: a 
randomized prospective trial comparing sodium phosphate to polyethylene glycol 
in predominantly elderly population. J Gastroenterol Hepatol, Vol.11, (1996), 
pp.103-7, ISSN: 0815-9319 (print); 1440-1746 (online). 
Ure, T; Dehghan, K; Vernava, A.M 3rd; Longo, W.E; Andrus, C.A & Daniel, G.L (1995). 
Colonoscopy in the elderly. Low risk, high yield. Surg Endosc, Vol.9, No.5, (May 
1995), pp.505-8, ISSN: 1432-2218 (online). 
Vanderhooft, J.E & Robinson, R.P (1994). Late infection of a bipolar prosthesis following 
endoscopy. A case report. J Bone Joint Surg Am, Vol.76, (1994), pp.744-6, ISSN: 
0021-9355. 
Van der Meer, J.T; Thompson, J; Valkenburg, H.A & Michel, M.F (1992). Epidemiology of 
bacterial endocarditis in The Netherlands. II. Antecedent procedures and use of 
prophylaxis. Arch Intern Med, Vol.152, No.9, (Sep 1992), pp.1869-73, ISSN: 0003-
9926 (print);1538-3679 (online). 
www.intechopen.com
 
Preparing for Colonoscopy 
 
41 
Vanner, SJ; MacDonald, PH; Paterson, WG; Prentice, RS; Da Costa, LR & Beck, IT. (1990).A 
randomized prospective trial comparing oral sodium phosphate with standard 
polyethylene glycol-based lavage solution (Golytely) in the preparation of patients 
for colonoscopy. Am J Gastroenterol,Vol.85, No.4, (Apr 1990), pp.422-7, ISSN: 0002-
9270.  
Wexner, SD. (1996).Preoperative preparation prior to colorectal surgery. Gastrointest 
Endosc,Vol.43, (1996), pp.530-1, ISSN: 0016-5107. 
Wexner, S.D.; Beck, D.E.; Baron, T.H.; Fanelli, R.D.; Hyman, N.; Shen, B.; Wasco, K.E. & 
American Society of Colon and Rectal Surgeons; American Society for 
Gastrointestinal Endoscopy & Society of American Gastrointestinal and Endoscopic 
Surgeons. (2006). A consensus document on bowel preparation before colonoscopy: 
prepared by a task force from the American Society of Colon and Rectal Surgeons 
(ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the 
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). 
Gastrointest Endosc,Vol. 63, No. 7, (Jun 2006), pp. 894-909, ISSN: 0016-5107 
Wilson, W; Taubert, K.A; Gewitz, M; Lockhart, P.B; Baddour, L.M; Levison, M; Bolger, A; 
Cabell, C.H; Takahashi, M; Baltimore, R.S; Newburger, J.W; Strom, B.L; Tani, L.Y; 
Gerber, M; Bonow, R.O; Pallasch, T; Shulman, S.T; Rowley, A.H; Burns, J.C; 
Ferrieri, P; Gardner, T; Goff, D & Durack, D.T (2007); American Heart Association 
Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; American Heart 
Association Council on Cardiovascular Disease in the Young; American Heart 
Association Council on Clinical Cardiology; American Heart Association Council 
on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes 
Research Interdisciplinary Working Group. Prevention of infective endocarditis: 
guidelines from the American Heart Association: a guideline from the American 
Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease 
Committee, Council on Cardiovascular Disease in the Young, and the Council on 
Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the 
Quality of Care and Outcomes Research Interdisciplinary Working Group. 
Circulation, Vol.116, No.15, (Oct 2007), pp.1736-54, ISSN: 0009-7322. 
Worthington, J; Thyssen, M; Chapman, G; Chapman, R & Geraint, M. (2008).A randomised 
controlled trial of a new 2 litre polyethylene glycol solution versus sodium 
picosulphate + magnesium citrate solution for bowel cleansing prior to 
colonoscopy. Curr Med Res Opin,Vol.24, Nov.2, (Feb 2008), pp.481-8, ISSN 0300-
7995. 
Wruble, L; Demicco, M; Medoff, J; Safdi, A; Bernstein, J; Dalke, D; Rose, M; Karlstadt, RG; 
Ettinger, N & Zhang, B. (2007).Residue-free sodium phosphate tablets (OsmoPrep) 
versus Visicol for colon cleansing: a randomized, investigator-blinded trial. 
Gastrointest Endosc,Vol.65, No.4,(Apr 2007), pp.660-70, ISSN: 0016-5107. 
Ziegenhagen, D.J.; Zehnter, E.; Tacke, W.; Gheorghiu, T. & Krius.W. (1992). Senna versus 
bisacodyl in addition to GoLytely lavage for colonoscopy preparation: A 
prospective randomized trial. Z Gastroenterol , Vol. 30, No. 1, (January 1992), pp. 17-
9, ISSN: 0044-2771. 
Zuckerman, M.J; Hirota, W.K; Adler, D.G; Davila, R.E; Jacobson, B.C; Leighton, J.A; Qureshi, 
W.A; Rajan, E; Hambrick, R.D; Fanelli, R.D; Baron, T.H & Faigel, D.O; Standards of 
Practice Committee of the American Society for Gastrointestinal Endoscopy (2005). 
www.intechopen.com
 
Endoscopic Procedures in Colon and Rectum 
 
42
ASGE guideline: the management of low-molecular-weight heparin and nonaspirin 
antiplatelet agents for endoscopic procedures. Gastrointest Endosc, Vol.61, No.2, 
(Feb 2005), pp.189-94, ISSN: 0016-5107. 
Zwas, F.R; Cirillo, N.W,; el-Serag, H.B &  Eisen, R.N (1996). Colonic mucosal abnormalities 
associated with oral sodium phosphate solution. Gastrointest Endosc, Vol.43, No.5, 
(May 1996), pp.463-6, ISSN: 0016-5107. 
www.intechopen.com
Endoscopic Procedures in Colon and Rectum
Edited by Prof. Jose Ribeiro Da Rocha
ISBN 978-953-307-677-5
Hard cover, 156 pages
Publisher InTech
Published online 07, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Endoscopic procedures in colon and rectum presents nine chapters which start with introductory ones like
screening by colonoscopy as the preparation and monitoring for this exam. In addition to these approaches
the book aims in the last four chapters to explain endoscopic diagnostic and therapeutic aspects in the colon
and rectum. The description of each text is very comprehensive, instructive and easy to understand and
presents the most current practices on the topics described. This book is recommended for general and
colorectal surgeons as it presents guidelines for diagnosis and treatment which are very well established.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Parakkal Deepak, Humberto Sifuentes, Muhammed Sherid and Eli D.Ehrenpreis (2011). Preparing for
Colonoscopy, Endoscopic Procedures in Colon and Rectum, Prof. Jose Ribeiro Da Rocha (Ed.), ISBN: 978-
953-307-677-5, InTech, Available from: http://www.intechopen.com/books/endoscopic-procedures-in-colon-
and-rectum/preparing-for-colonoscopy-2
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
